SCHEMBL13019905

SCHEMBL13019905

Nc1ncnc2c1c(-c1ccc(Cl)cc1)nn2C(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 8/20 0.58
▸ BTK Q06187 4/20 0.57
▸ PIK3CD O00329 2/20 0.53
▸ PIK3CA P42336 2/20 0.53
▸ PIK3CB P42338 2/20 0.53
▸ PIK3CG P48736 2/20 0.53
▸ PRKDC P78527 2/20 0.53
▸ FYN P06241 4/20 0.52
▸ LYN P07948 3/20 0.52
▸ BLK P51451 3/20 0.52
▸ ABL1 P00519 3/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ EGFR P00533 2/20 0.51
▸ LCK P06239 2/20 0.51
▸ YES1 P07947 2/20 0.51
▸ FGR P09769 2/20 0.51
▸ DAPK3 O43293 1/20 0.51
▸ RIPK2 O43353 1/20 0.51
▸ HCK P08631 1/20 0.51
▸ PDGFRB P09619 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17264218 0.89 BTK (0.71) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL13019903 0.84 SRC (0.58) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL3781508 0.82 SRC (0.58) SRCBTKFYNLYNBLK
SCHEMBL3778669 0.82 SRC (0.58) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL13019941 0.79 SRC (0.60) SRCBTKFYNLYNBLK
SCHEMBL10098381 0.78 SRC (0.57) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL3788008 0.78 SRC (0.62) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL13019685 0.77 PIK3CD (0.73) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL13064038 0.76 ABL1 (0.48) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL13064031 0.75 SRC (0.58) SRCBTKPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885BTK 3999/4885PIK3CD 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback